Skip to main content
. 2015 Jun 8;10(6):e0123967. doi: 10.1371/journal.pone.0123967

Fig 1. Combination of TUSC2 stable expression and erlotinib treatment inhibits tumor cell growth significantly.

Fig 1

TUSC2-deficient wild type EGFR NSCLC A549, H1299, and H157 cells were treated with 1μg/ml doxycycline to induce TUSC2 expression, treated with 2.3μM erlotinib, and assayed for viability using the SRB assay. After adjusting for multiple comparisons, a significant inhibitory effect was observed for TUSC2 and erlotinib combined treatment compared to any other group by ANOVA (P<0.0001). Data shown is expressed as the mean ± SE. Values represent the mean of three independent experiments.